Timeline of incretin therapeutics: difference between revisions

Diff·revision 14 → 15·01:19, 6 Apr 2025

Difference between revision 14 and revision 15 of Timeline of incretin therapeutics. 13 lines changed; the page grew by 803 bytes.

Revision 14 — 07:46, 12 Mar 2025 TalkPageTaro (talk) fix the amino-acid substitution — position 8, not position 2 3,151 bytes ±0	Revision 15 — 01:19, 6 Apr 2025 DiffWatchDov (talk) add the molecular formula to the infobox 3,954 bytes +803
39	The 2016 result changed the framing of the class from glucose-lowering to outcome-modifying, and it did so in a period when cardiovascular outcome trials were being run principally to exclude harm.{{r\|drucker2018}}	39	The 2016 result changed the framing of the class from glucose-lowering to outcome-modifying, and it did so in a period when cardiovascular outcome trials were being run principally to exclude harm.{{r\|drucker2018}}
40		40
+		41	== Second generation and beyond ==
+		42	\| Year \| Event \|
+		43	\|---\|---\|
+		44	\| 2017 \| [[Semaglutide]] approved for type 2 diabetes \|
+		45	\| 2019 \| [[Oral semaglutide]] approved \|
+		46	\| 2021 \| [[STEP trial programme]] first results published; semaglutide 2.4 mg approved for weight management \|
+		47	\| 2022 \| [[Tirzepatide]] approved for type 2 diabetes \|
+		48	\| 2023 \| [[SURMOUNT trial programme]] first results published; [[Retatrutide]] phase 2 published \|
+		49	\| 2023 \| [[SELECT trial]] reports cardiovascular benefit without diabetes \|
+		50	\| 2024 \| [[FLOW trial]] reports renal benefit \|
+		51
+		52	The 2021 and 2023 publications are the ones that moved the field from diabetes into obesity medicine at scale, and the 2023 and 2024 outcome trials are what distinguish these agents from weight-loss interventions without outcome evidence.{{r\|ada2024}}
+		53
41	== References ==	54	== References ==
42	{{reflist}}	55	{{reflist}}